Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 2

Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications

Authors Paul N Knoebl

Published 6 June 2008 Volume 2008:2(2) Pages 285—296


Paul N Knoebl

Department of Medicine 1, Division Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria

Abstract: The protein C pathway has an important function in regulating and modulating blood coagulation and ensuring patency of the microcirculation. Protein C deficiency leads to macro- and microvascular thrombosis. Congenital severe protein C deficiency is a life-threatening state with neonatal purpura fulminans and pronounced coagulopathy. Patients with heterozygous protein C deficiency have an increased risk for thromboembolic events or experience coumarin-induced skin necrosis during initiation of coumarin therapy. Replacement with protein C concentrates is an established therapy of congenital protein C deficiency, resulting in rapid resolving of coagulopathy and thrombosis without reasonable side effects. This article summarizes the current knowledge on protein C replacement therapy in congenital protein C deficiency.

Keywords: protein C, deficiency, replacement therapy, purpura fulminans, coagulopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Case-control association study of ABCB1 gene and major depressive disorder in a local Chinese Han population

Xie WW, Zhang L, Wu RR, Yu Y, Zhao JP, Li LH

Neuropsychiatric Disease and Treatment 2015, 11:1967-1971

Published Date: 4 August 2015

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Wei Y, Guo J, Zheng X, Wu J, Zhou Y, Yu Y, Ye Y, Zhang L, Zhao L

International Journal of Nanomedicine 2014, 9:3623-3630

Published Date: 1 August 2014

Future developments in biliary stenting

Hair CD, Sejpal DV

Clinical and Experimental Gastroenterology 2013, 6:91-99

Published Date: 24 June 2013

Metastatic gastric cancer – focus on targeted therapies

Meza-Junco J, Sawyer MB

Biologics: Targets and Therapy 2012, 6:137-146

Published Date: 20 June 2012

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

Tariq I Mughal, Andrew Schrieber

Biologics: Targets and Therapy 2010, 4:315-323

Published Date: 2 December 2010

Highly efficient human serum filtration with water-soluble nanoporous nanoparticles

Antonella Pujia, Francesco De Angelis, Domenica Scumaci, et al

International Journal of Nanomedicine 2010, 5:1005-1015

Published Date: 19 November 2010

A preliminary study of the use of bioimpedance in the screening of squamous tongue cancer

Congo Tak-Shing Ching, Tai-Ping Sun, Su-Hua Huang, et al

International Journal of Nanomedicine 2010, 5:213-220

Published Date: 17 March 2010

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)

Leigh D Church, Sinisa Savic, Michael F McDermott

Biologics: Targets and Therapy 2008, 2:733-742

Published Date: 5 December 2008

Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures

Neil Ghodadra, Kern Singh

Biologics: Targets and Therapy 2008, 2:345-354

Published Date: 12 September 2008